Company Announcements

TR-1: Standard form for notification of major holdings - April 2019.. Read More →

Renalytix AI plc announces publication of results generated by a confirmation study... Read More →

Renalytix AI plc announces its inaugural unaudited interim results for the six months ended 31 December 2018... Read More →

Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai... Read More →

Renalytix AI announces that it will host investor briefings focused on AI-enabled diagnostics and kidney disease on Monday 25 March 2019.. Read More →

Renalytix AI announces the appointment of Stifel as the Company’s nominated adviser and joint broker with immediate effect. N+1 Singer will continue to act as.. Read More →

Renalytix AI announces the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of clinical trial precision medicine services located in.. Read More →

Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programmes.. Read More →

Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators.. Read More →

This announcement relates solely to ordinary shares in the Company which were distributed to certain qualifying shareholders owning EKF Diagnostic Holdings plc shares prior to.. Read More →

Renalytix AI announces the exercise of its option for the exclusive license from the Icahn School of Medicine at Mount Sinai of a portfolio of.. Read More →

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares. .. Read More →

Renalytix AI notes the announcement today by EKF Diagnostics Holdings plc and confirms that it has agreed a different resolution to the requirement for one.. Read More →

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 5,970 ordinary shares. .. Read More →

TR-1: Standard form for notification of major holdings - December 2018.. Read More →

TR-1: Standard form for notification of major holdings.. Read More →

TR-1: Standard form for notification of major holdings.. Read More →

Renalytix AI plc announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of.. Read More →

Renalytix AI plc, a developer of artificial intelligence enabled clinical diagnostic solutions for kidney disease, announces the admission of its ordinary shares to trading on.. Read More →

Renalytix AI plc announces that, further to the announcement by EKF Diagnostics Holdings plc (“EKF”) on 31 October confirming that RenalytixAI’s had successfully raised £22.25.. Read More →

Today RenalytixAI announced a successful, conditional equity fundraising, having secured funding commitments via a placing and subscription of not less than £21 million. The Company.. Read More →

Renalytix AI plc announces that it has conditionally raised gross funds of a minimum of £21 million in connection with its previously announced equity fundraising.. Read More →

Further to the Company’s announcement on 4 July 2018 in relation to Renalytix AI plc (“Renalytix AI”), EKF announces that it intends to undertake further.. Read More →

Renalytix AI PLC to develop Artificial Intelligence solutions for early identification and management of kidney disease.. Read More →

Mount Sinai and Renalytix AI today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection,.. Read More →